GLP-1类肥胖药物在治疗激素失调疾病多囊卵巢综合征（PCOS）方面显示出初步疗效。[1]这一发现为全球数百万患者带来希望，PCOS影响全球约八分之一的女性。[1]
来自科罗拉多州的18岁患者Charlotte Touzalin参加了相关临床试验，在连续十个月每周注射semaglutide后取得显著成效。[1]研究中的11名参与者中有8人体重至少下降10%，中位体重减轻约42磅，睾酮水平中位下降52%。[1]此外，6名女性的月经周期有所增加，其中4人恢复到每月一次的正常月经。[1]
Dr. Melanie Cree领导了三项关于GLP-1药物治疗PCOS的研究，相关数据已于6月发表在《生育与不孕症》期刊上。[1]然而，由于这类药物尚未获批用于治疗PCOS，保险公司拒绝为患者覆盖治疗费用，导致许多患者难以获得治疗。Touzalin在6月停止用药，因为失去了研究提供的免费药物。[1]
Researchers have found that GLP-1 medications, commonly used for weight loss, demonstrate early potential in treating polycystic ovary syndrome (PCOS), a hormonal disorder affecting approximately one in eight women globally.[1] A clinical trial led by Dr. Melanie Cree tested these drugs, with results published in June in the journal Fertility and Sterility.[1] Among eleven study participants, eight experienced weight loss of at least 10 percent, with a median reduction of approximately 42 pounds, while median testosterone levels declined by 52 percent.[1] Additionally, six women reported increased menstrual frequency, with four achieving regular monthly cycles.[1]
Charlotte Touzalin, an 18-year-old from Colorado, participated in the trial by receiving weekly injections of semaglutide for ten consecutive months.[1] Her experience exemplified the treatment's effects: she lost weight, her testosterone levels dropped, and she experienced the return of normal menstrual cycles.[1] However, when she stopped treatment in June after losing access to the medication provided through the research program, maintaining these improvements became difficult.[1]
Despite these promising results, widespread access to GLP-1 medications for PCOS treatment remains limited. Insurance companies refuse to cover these drugs for PCOS since they have not been formally approved for this indication, leaving many patients unable to afford the therapy.[1]